Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
Cross-reactivity against human coronaviruses with Flebogamma DIF and Gamunex -C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and M...
Gespeichert in:
| Veröffentlicht in: | Immunotherapy 2020-12, Vol.12 (17), p.1247-1255 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1255 |
|---|---|
| container_issue | 17 |
| container_start_page | 1247 |
| container_title | Immunotherapy |
| container_volume | 12 |
| creator | Díez, José María Romero, Carolina Vergara-Alert, Júlia Belló-Perez, Melissa Rodon, Jordi Honrubia, José Manuel Segalés, Joaquim Sola, Isabel Enjuanes, Luis Gajardo, Rodrigo |
| description | Cross-reactivity against human coronaviruses with Flebogamma
DIF and Gamunex
-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV).
Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods.
All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV.
The tested IVIG contain antibodies with significant
cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19. |
| doi_str_mv | 10.2217/imt-2020-0220 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7480323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2501458795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-619787d53b07b2ec4271aa440e21b810b90ddd062c52caeb2a3ee458fc94b3f93</originalsourceid><addsrcrecordid>eNp1kctrFTEUxoNU7EOXbstA16l5zWRmI5SLLygIVsVdSDJnblNmkmseF-pfb4ZbL7pwlZOTX77zcT6EXlNyzRiVb9ySMSOMYMIYeYbOqGwJlkL0J8ea_zhF5yk9ENIJ2YkX6JSzgRDW8TPkNzGkhD2UHPXsfunsgm-0zW7v8mOjt9r5lJu7my93eBO-Y9a41OwiJPC5cb6xJcZazhXdazdrM0NtV609-FBS45al-LCdgylzVXqJnk96TvDq6bxA396_-7r5iG8_f_i0ubnFVgw8444Ospdjyw2RhoEVTFKthSDAqOkpMQMZx5F0zLbMajBMcwDR9pMdhOHTwC_Q24PurpgFRgurpVntolt0fFRBO_Xvi3f3ahv2SoqecMarwNWTQAw_C6SsHkKJvnpWrCW0zpJDWyl8oOy6xQjTcQIlao1H1XjUGo9a46n85d-2jvSfPCowHICp5FK3bB14C-pwqz-cdR7-I_4bDRGiWA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501458795</pqid></control><display><type>article</type><title>Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins</title><source>MEDLINE</source><source>PubMed Central</source><creator>Díez, José María ; Romero, Carolina ; Vergara-Alert, Júlia ; Belló-Perez, Melissa ; Rodon, Jordi ; Honrubia, José Manuel ; Segalés, Joaquim ; Sola, Isabel ; Enjuanes, Luis ; Gajardo, Rodrigo</creator><creatorcontrib>Díez, José María ; Romero, Carolina ; Vergara-Alert, Júlia ; Belló-Perez, Melissa ; Rodon, Jordi ; Honrubia, José Manuel ; Segalés, Joaquim ; Sola, Isabel ; Enjuanes, Luis ; Gajardo, Rodrigo</creatorcontrib><description>Cross-reactivity against human coronaviruses with Flebogamma
DIF and Gamunex
-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV).
Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods.
All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV.
The tested IVIG contain antibodies with significant
cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.</description><identifier>ISSN: 1750-743X</identifier><identifier>EISSN: 1750-7448</identifier><identifier>DOI: 10.2217/imt-2020-0220</identifier><identifier>PMID: 32900263</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Antibodies, Neutralizing - immunology ; Antibodies, Viral - immunology ; Antibodies, Viral - pharmacology ; Betacoronavirus - drug effects ; Betacoronavirus - immunology ; Cell culture ; Coronaviridae ; Coronavirus Infections - immunology ; Coronaviruses ; COVID-19 ; Cross Reactions - immunology ; cross-neutralization ; Cross-reactivity ; Cytotoxicity ; Humans ; Immunoglobulins ; Immunoglobulins, Intravenous - immunology ; Immunoglobulins, Intravenous - pharmacology ; Infectivity ; Intravenous administration ; intravenous immunoglobulin ; MERS-CoV ; Middle East respiratory syndrome ; Middle East Respiratory Syndrome Coronavirus - drug effects ; Middle East Respiratory Syndrome Coronavirus - immunology ; Pandemics ; Pneumonia, Viral - immunology ; SARS-CoV ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Short Communication ; Viruses</subject><ispartof>Immunotherapy, 2020-12, Vol.12 (17), p.1247-1255</ispartof><rights>2020 Jose Maria Diez (on behalf of co-authors)</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Jose Maria Diez (on behalf of co-authors) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-619787d53b07b2ec4271aa440e21b810b90ddd062c52caeb2a3ee458fc94b3f93</citedby><cites>FETCH-LOGICAL-c493t-619787d53b07b2ec4271aa440e21b810b90ddd062c52caeb2a3ee458fc94b3f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480323/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480323/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32900263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Díez, José María</creatorcontrib><creatorcontrib>Romero, Carolina</creatorcontrib><creatorcontrib>Vergara-Alert, Júlia</creatorcontrib><creatorcontrib>Belló-Perez, Melissa</creatorcontrib><creatorcontrib>Rodon, Jordi</creatorcontrib><creatorcontrib>Honrubia, José Manuel</creatorcontrib><creatorcontrib>Segalés, Joaquim</creatorcontrib><creatorcontrib>Sola, Isabel</creatorcontrib><creatorcontrib>Enjuanes, Luis</creatorcontrib><creatorcontrib>Gajardo, Rodrigo</creatorcontrib><title>Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins</title><title>Immunotherapy</title><addtitle>Immunotherapy</addtitle><description>Cross-reactivity against human coronaviruses with Flebogamma
DIF and Gamunex
-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV).
Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods.
All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV.
The tested IVIG contain antibodies with significant
cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.</description><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibodies, Viral - pharmacology</subject><subject>Betacoronavirus - drug effects</subject><subject>Betacoronavirus - immunology</subject><subject>Cell culture</subject><subject>Coronaviridae</subject><subject>Coronavirus Infections - immunology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cross Reactions - immunology</subject><subject>cross-neutralization</subject><subject>Cross-reactivity</subject><subject>Cytotoxicity</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunoglobulins, Intravenous - immunology</subject><subject>Immunoglobulins, Intravenous - pharmacology</subject><subject>Infectivity</subject><subject>Intravenous administration</subject><subject>intravenous immunoglobulin</subject><subject>MERS-CoV</subject><subject>Middle East respiratory syndrome</subject><subject>Middle East Respiratory Syndrome Coronavirus - drug effects</subject><subject>Middle East Respiratory Syndrome Coronavirus - immunology</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - immunology</subject><subject>SARS-CoV</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Short Communication</subject><subject>Viruses</subject><issn>1750-743X</issn><issn>1750-7448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kctrFTEUxoNU7EOXbstA16l5zWRmI5SLLygIVsVdSDJnblNmkmseF-pfb4ZbL7pwlZOTX77zcT6EXlNyzRiVb9ySMSOMYMIYeYbOqGwJlkL0J8ea_zhF5yk9ENIJ2YkX6JSzgRDW8TPkNzGkhD2UHPXsfunsgm-0zW7v8mOjt9r5lJu7my93eBO-Y9a41OwiJPC5cb6xJcZazhXdazdrM0NtV609-FBS45al-LCdgylzVXqJnk96TvDq6bxA396_-7r5iG8_f_i0ubnFVgw8444Ospdjyw2RhoEVTFKthSDAqOkpMQMZx5F0zLbMajBMcwDR9pMdhOHTwC_Q24PurpgFRgurpVntolt0fFRBO_Xvi3f3ahv2SoqecMarwNWTQAw_C6SsHkKJvnpWrCW0zpJDWyl8oOy6xQjTcQIlao1H1XjUGo9a46n85d-2jvSfPCowHICp5FK3bB14C-pwqz-cdR7-I_4bDRGiWA</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Díez, José María</creator><creator>Romero, Carolina</creator><creator>Vergara-Alert, Júlia</creator><creator>Belló-Perez, Melissa</creator><creator>Rodon, Jordi</creator><creator>Honrubia, José Manuel</creator><creator>Segalés, Joaquim</creator><creator>Sola, Isabel</creator><creator>Enjuanes, Luis</creator><creator>Gajardo, Rodrigo</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20201201</creationdate><title>Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins</title><author>Díez, José María ; Romero, Carolina ; Vergara-Alert, Júlia ; Belló-Perez, Melissa ; Rodon, Jordi ; Honrubia, José Manuel ; Segalés, Joaquim ; Sola, Isabel ; Enjuanes, Luis ; Gajardo, Rodrigo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-619787d53b07b2ec4271aa440e21b810b90ddd062c52caeb2a3ee458fc94b3f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibodies, Viral - pharmacology</topic><topic>Betacoronavirus - drug effects</topic><topic>Betacoronavirus - immunology</topic><topic>Cell culture</topic><topic>Coronaviridae</topic><topic>Coronavirus Infections - immunology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cross Reactions - immunology</topic><topic>cross-neutralization</topic><topic>Cross-reactivity</topic><topic>Cytotoxicity</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunoglobulins, Intravenous - immunology</topic><topic>Immunoglobulins, Intravenous - pharmacology</topic><topic>Infectivity</topic><topic>Intravenous administration</topic><topic>intravenous immunoglobulin</topic><topic>MERS-CoV</topic><topic>Middle East respiratory syndrome</topic><topic>Middle East Respiratory Syndrome Coronavirus - drug effects</topic><topic>Middle East Respiratory Syndrome Coronavirus - immunology</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - immunology</topic><topic>SARS-CoV</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Short Communication</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Díez, José María</creatorcontrib><creatorcontrib>Romero, Carolina</creatorcontrib><creatorcontrib>Vergara-Alert, Júlia</creatorcontrib><creatorcontrib>Belló-Perez, Melissa</creatorcontrib><creatorcontrib>Rodon, Jordi</creatorcontrib><creatorcontrib>Honrubia, José Manuel</creatorcontrib><creatorcontrib>Segalés, Joaquim</creatorcontrib><creatorcontrib>Sola, Isabel</creatorcontrib><creatorcontrib>Enjuanes, Luis</creatorcontrib><creatorcontrib>Gajardo, Rodrigo</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Díez, José María</au><au>Romero, Carolina</au><au>Vergara-Alert, Júlia</au><au>Belló-Perez, Melissa</au><au>Rodon, Jordi</au><au>Honrubia, José Manuel</au><au>Segalés, Joaquim</au><au>Sola, Isabel</au><au>Enjuanes, Luis</au><au>Gajardo, Rodrigo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins</atitle><jtitle>Immunotherapy</jtitle><addtitle>Immunotherapy</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>12</volume><issue>17</issue><spage>1247</spage><epage>1255</epage><pages>1247-1255</pages><issn>1750-743X</issn><eissn>1750-7448</eissn><abstract>Cross-reactivity against human coronaviruses with Flebogamma
DIF and Gamunex
-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV).
Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods.
All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV.
The tested IVIG contain antibodies with significant
cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>32900263</pmid><doi>10.2217/imt-2020-0220</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1750-743X |
| ispartof | Immunotherapy, 2020-12, Vol.12 (17), p.1247-1255 |
| issn | 1750-743X 1750-7448 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7480323 |
| source | MEDLINE; PubMed Central |
| subjects | Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Antibodies, Viral - pharmacology Betacoronavirus - drug effects Betacoronavirus - immunology Cell culture Coronaviridae Coronavirus Infections - immunology Coronaviruses COVID-19 Cross Reactions - immunology cross-neutralization Cross-reactivity Cytotoxicity Humans Immunoglobulins Immunoglobulins, Intravenous - immunology Immunoglobulins, Intravenous - pharmacology Infectivity Intravenous administration intravenous immunoglobulin MERS-CoV Middle East respiratory syndrome Middle East Respiratory Syndrome Coronavirus - drug effects Middle East Respiratory Syndrome Coronavirus - immunology Pandemics Pneumonia, Viral - immunology SARS-CoV SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Short Communication Viruses |
| title | Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T12%3A12%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cross-neutralization%20activity%20against%20SARS-CoV-2%20is%20present%20in%20currently%20available%20intravenous%20immunoglobulins&rft.jtitle=Immunotherapy&rft.au=D%C3%ADez,%20Jos%C3%A9%20Mar%C3%ADa&rft.date=2020-12-01&rft.volume=12&rft.issue=17&rft.spage=1247&rft.epage=1255&rft.pages=1247-1255&rft.issn=1750-743X&rft.eissn=1750-7448&rft_id=info:doi/10.2217/imt-2020-0220&rft_dat=%3Cproquest_pubme%3E2501458795%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501458795&rft_id=info:pmid/32900263&rfr_iscdi=true |